Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Lessened by Litman Gregory Wealth Management LLC

Litman Gregory Wealth Management LLC lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 157,946 shares of the medical research company’s stock after selling 3,425 shares during the quarter. Edwards Lifesciences makes up 1.0% of Litman Gregory Wealth Management LLC’s portfolio, making the stock its 29th largest holding. Litman Gregory Wealth Management LLC’s holdings in Edwards Lifesciences were worth $11,693,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences in the third quarter worth $40,000. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences in the fourth quarter valued at $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $72.41 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $42.71 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.65 and a beta of 1.11. The stock has a fifty day moving average price of $72.49 and a 200 day moving average price of $69.97. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $2,195,180 over the last 90 days. Insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent analyst reports. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a report on Thursday. The Goldman Sachs Group boosted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.